$125.10
-1.29-1.02%
Last update: Oct 26, 6:21 AM
Palvella Therapeutics Inc (PVLA) Stock Price, Quote, News & History
PVLANASDAQ
Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous malformations.
You can purchase shares of Palvella Therapeutics (NASDAQ:PVLA) through any online brokerage.
Other companies in Palvella Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Palvella Therapeutics has a consensus price target of $163.63.
The stock price for Palvella Therapeutics (NASDAQ: PVLA) is $125.6 last updated October 26, 2026 at 6:21 AM EDT.
There are no upcoming dividends for Palvella Therapeutics.
Palvella Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Palvella Therapeutics.
Palvella Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin...
